Filtered By:
Condition: Diabetes Mellitus
Drug: SGLT2 Inhibitors
Countries: Taiwan Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
Conclusions/interpretationIn people with diabetes, GLP1RA use was associated with significantly reduced risks of MALE compared with SGLT2i within the first 2 years after initiation, especially among people with diabetic neuropathy.Graphical abstract
Source: Diabetologia - August 9, 2022 Category: Endocrinology Source Type: research
